Literature DB >> 12604533

Comparing pharmacokinetics of amoxicillin given twice or three times per day to children older than 3 months with pneumonia.

Walter Fonseca1, Kalle Hoppu, Luís C Rey, João Amaral, Shamim Qazi.   

Abstract

For children with ambulatory pneumonia, the World Health Organization (WHO) recommends oral amoxicillin (15 mg/kg of body weight/dose) thrice daily (t.i.d.) or oral cotrimoxazole (4 mg of trimethoprim/kg/dose) twice daily (b.i.d.). The more frequent amoxicillin dosing may lead to compliance problems. To compare the pharmacokinetics and levels of amoxicillin in plasma in the current WHO acute respiratory infection recommendations with the 25-mg/kg/dose b.i.d. regimen, we performed a two-group parallel study of 66 children ages 3 to 59 months with pneumonia. Amoxicillin was given orally at 25 mg/kg/dose b.i.d. or 15 mg/kg/dose t.i.d. Amoxicillin concentrations were determined by high-performance liquid chromatography after the first dose on days 1 and 3. After the first dose on day 1, the mean area under the concentration-time curve (AUC) for amoxicillin after the 25-mg/kg dose was 54.7 versus 24.9 micro g. h/ml after the 15-mg/kg dose. After the first dose on day 3, the mean AUC was 44.1 versus 28.5 micro g. h/ml. All but two children had plasma amoxicillin concentrations above 0.5 micro g/ml for >50% of the dose interval on both days. Six children on day 1 and five children on day 3 had concentrations above 1.0 micro g/ml for <50% of the dose interval. On day 1, 16 of 27 children in the b.i.d. group and 11 of 26 children in the t.i.d. group had concentrations that were above 2.0 micro g/ml for <50% of the dose interval, and on day 3, 18 of 31 children in the b.i.d. group and 8 of 31 children in the t.i.d. group had concentrations that were above 2.0 micro g/ml for <50% of the dose interval. Amoxicillin b.i.d. is a feasible alternative for t.i.d. dosing. To lengthen the time above the MIC at higher concentration levels, a 30- to 40-mg/kg/dose b.i.d. should be considered instead of the 25 mg/kg/dose used in this study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12604533      PMCID: PMC149282          DOI: 10.1128/AAC.47.3.997-1001.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Efficacy of beta-lactam antibiotics: integration of pharmacokinetics and pharmacodynamics.

Authors:  O Cars
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

2.  Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan.

Authors:  T D Mastro; A Ghafoor; N K Nomani; Z Ishaq; F Anwar; D M Granoff; J S Spika; C Thornsberry; R R Facklam
Journal:  Lancet       Date:  1991-01-19       Impact factor: 79.321

3.  Acute respiratory infections in children. A global public-health problem.

Authors:  J Chretien; W Holland; P Macklem; J Murray; A Woolcock
Journal:  N Engl J Med       Date:  1984-04-12       Impact factor: 91.245

4.  Prospective clinical trial on the efficacy of amoxycillin administered twice or four times daily in children with respiratory tract infections.

Authors:  F D Daschner; U Behre; A Dalhoff
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

5.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

6.  Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children.

Authors:  C M Ginsburg; G H McCracken; M L Thomas; J Clahsen
Journal:  Pediatrics       Date:  1979-11       Impact factor: 7.124

Review 7.  Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.

Authors:  G L Drusano; W A Craig
Journal:  J Chemother       Date:  1997-05       Impact factor: 1.714

8.  Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group.

Authors:  S L Deeks; R Palacio; R Ruvinsky; D A Kertesz; M Hortal; A Rossi; J S Spika; J L Di Fabio
Journal:  Pediatrics       Date:  1999-02       Impact factor: 7.124

9.  Antimicrobial susceptibility patterns of Haemophilus isolates from children in eleven developing nations. BOSTID Haemophilus Susceptibility Study Group.

Authors:  G A Weinberg; E D Spitzer; P R Murray; A Ghafoor; J Montgomery; T E Tupasi; D M Granoff
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

10.  Assay of amoxicillin and clavulanic acid, the components of Augmentin, in biological fluids with high-performance liquid chromatography.

Authors:  M Foulstone; C Reading
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

View more
  12 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Variations in amoxicillin pharmacokinetic/pharmacodynamic parameters may explain treatment failures in acute otitis media.

Authors:  Michael E Pichichero; Michael D Reed
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  Case management of childhood pneumonia in developing countries.

Authors:  Philip Ayieko; Mike English
Journal:  Pediatr Infect Dis J       Date:  2007-05       Impact factor: 2.129

4.  Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment.

Authors:  Yael R Nobel; Laura M Cox; Francis F Kirigin; Nicholas A Bokulich; Shingo Yamanishi; Isabel Teitler; Jennifer Chung; Jiho Sohn; Cecily M Barber; David S Goldfarb; Kartik Raju; Sahar Abubucker; Yanjiao Zhou; Victoria E Ruiz; Huilin Li; Makedonka Mitreva; Alexander V Alekseyenko; George M Weinstock; Erica Sodergren; Martin J Blaser
Journal:  Nat Commun       Date:  2015-06-30       Impact factor: 14.919

Review 5.  Treatment of Community-Acquired Pneumonia: Are All Countries Treating Children in the Same Way? A Literature Review.

Authors:  Daniele Donà; Dora Luise; Liviana Da Dalt; Carlo Giaquinto
Journal:  Int J Pediatr       Date:  2017-11-06

6.  Safety, Effectiveness and Feasibility of Outpatient Management of Children with Pneumonia with Chest Indrawing at Port Moresby General Hospital, Papua New Guinea.

Authors:  Rose Morre; Kone Sobi; Wendy Pameh; Paulus Ripa; John D Vince; Trevor Duke
Journal:  J Trop Pediatr       Date:  2019-02-01       Impact factor: 1.165

7.  Efficacy of oral amoxicillin-clavulanate or azithromycin for non-severe respiratory exacerbations in children with bronchiectasis (BEST-1): a multicentre, three-arm, double-blind, randomised placebo-controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Robert S Ware; Catherine A Byrnes; Peter S Morris; I Brent Masters; Gabrielle B McCallum; Michael J Binks; Heidi Smith-Vaughan; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; André Schultz; Mark Chatfield; Paul J Torzillo; Anne B Chang
Journal:  Lancet Respir Med       Date:  2019-08-16       Impact factor: 30.700

Review 8.  Childhood community-acquired pneumonia: A review of etiology- and antimicrobial treatment studies.

Authors:  Gerdien A Tramper-Stranders
Journal:  Paediatr Respir Rev       Date:  2017-07-15       Impact factor: 2.726

9.  Impact of community management of fever (using antimalarials with or without antibiotics) on childhood mortality: a cluster-randomized controlled trial in Ghana.

Authors:  Margaret A Chinbuah; Piet A Kager; Mercy Abbey; Margaret Gyapong; Elizabeth Awini; Justice Nonvignon; Martin Adjuik; Moses Aikins; Franco Pagnoni; John O Gyapong
Journal:  Am J Trop Med Hyg       Date:  2012-11       Impact factor: 2.345

10.  Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial.

Authors:  Vikas Goyal; Keith Grimwood; Catherine A Byrnes; Peter S Morris; I Brent Masters; Robert S Ware; Gabrielle B McCallum; Michael J Binks; Julie M Marchant; Peter van Asperen; Kerry-Ann F O'Grady; Anita Champion; Helen M Buntain; Helen Petsky; Paul J Torzillo; Anne B Chang
Journal:  Lancet       Date:  2018-09-18       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.